ArticleMolecular vision2011
Tear levels of neuropeptides increase after specific allergen challenge in allergic conjunctivitis.
Article in Molecular vision, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 57 citations in OpenAlex.
- Role of tear vasoactive intestinal peptide on dry eyes after laser keratorefractive surgery.BMC ophthalmology · 2023Trial
- Mediator profiles in tears during the conjunctival response induced by allergic reaction in the nasal mucosa.Molecular vision · 2013Trial
- Macrophage Extracellular Vesicles: Therapeutic Strategies for Corneal Fibrosis in Rare Diseases.Biomolecules · 2026Review
- Pathophysiological and molecular insights into allergic conjunctivitis: an expanding analysis of immunological endotypes.Frontiers in allergy · 2026Review
- Tear neuropeptides are associated with clinical symptoms and signs of dry eye patients.Annals of medicine · 2025Article
- Inflammatory profile of keratoconic corneal epithelium.BMC ophthalmology · 2023Observational
- Obstruction of the Tear Drainage Altered Lacrimal Gland Structure and Function.Investigative ophthalmology & visual science · 2023Article
- Immunomodulatory Role of Neuropeptides in the Cornea.Biomedicines · 2022Review
- Fluorescence Sensing Technologies for Ophthalmic Diagnosis.ACS sensors · 2022Review
- Mucosal immunology of the ocular surface.Mucosal immunology · 2022Review
- Immunity and pain in the eye: focus on the ocular surface.Clinical and experimental immunology · 2022Review
- Understanding Vernal Keratoconjunctivitis: Beyond Allergic Mechanisms.Life (Basel, Switzerland) · 2021Review
- Naso-ocular neuropeptide interactions in allergic rhinoconjunctivitis, rhinitis, and conjunctivitis.The World Allergy Organization journal · 2021Article
- The ocular surface immune system through the eyes of aging.The ocular surface · 2021Review
- Potential Biomarkers for Allergic Conjunctival Diseases.Eye & contact lens · 2020Review
- Non-invasive objective and contemporary methods for measuring ocular surface inflammation in soft contact lens wearers - A review.Contact lens & anterior eye : the journal of the British Contact Lens Association · 2017Review
- Neurotrophic factors and corneal nerve regeneration.Neural regeneration research · 2017Review
- Neuroanatomy and Neurochemistry of Mouse Cornea.Investigative ophthalmology & visual science · 2016Article
- Tear fluid biomarkers in ocular and systemic disease: potential use for predictive, preventive and personalised medicine.The EPMA journal · 2016Review
- Severing corneal nerves in one eye induces sympathetic loss of immune privilege and promotes rejection of future corneal allografts placed in either eye.American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeGrowing evidence is showing a role of neurogenic inflammation in allergic reactions, with sensory and autonomic nerve fibers releasing neuromediators, which may actively participate in the allergic inflammatory cascade. Although the cornea is the most densely innervated tissue of the human body, little is known on the role of neuromediators at the ocular surface. In this study, we aimed at evaluating the role of substance P (SP), calcitonine gene related peptide (CGRP), neuropeptide Y (NPY) and vasoactive intestinal peptide (VIP) in allergic reactions of the ocular surface.
methodsFifteen patients with allergic conjunctivitis (6 female, 9 male, mean age 30±8 years) in non-active phase, and 10 age-matched healthy subjects were included in this study. The conjunctival provocation test (CPT) with allergen was performed in all allergic patients and in 5 healthy subjects. Tear samples were collected and the tear content of VIP, NPY, CGRP, and SP was measured by ELISA at baseline and after CPT. The Mann-Whitney U-test and Wilcoxon test were used to compare neuromediator tear levels.
resultsNo significant differences in neuropeptide tear levels were observed between healthy and allergic patients in non-active phase. CPT induced conjunctival hyperemia and itching in all allergic patients, while no reaction was observed in the control eyes and in healthy subjects. In allergic patients SP, CGRP, and VIP, but not NPY, were significantly higher after CPT as compared to baseline (SP: 3.9±1.3 ng/ml versus 5.8±1.1 ng/ml, p=0.011; CGRP: 5.5±2.3 ng/ml versus 7.3±2.7 ng/ml; p=0.002; VIP: 4±0.9 ng/ml versus 5.1±1.5 ng/ml, p=0.007). No significant changes were observed in the control eyes of allergic patients challenged with diluent and in healthy subjects after allergen provocation.
conclusionsLocally-released neuromediators may participate in modulating the allergic response of the ocular surface.
Indexed as
Identifiers
21245958PMC3021574W2164766687What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.